Ultragenyx Pharmaceutical (NASDAQ:RARE) Cut to “Neutral” at Bank of America

Bank of America lowered shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) from a buy rating to a neutral rating in a research report report published on Thursday, MarketBeat Ratings reports.

A number of other analysts also recently weighed in on the stock. Morgan Stanley increased their target price on shares of Ultragenyx Pharmaceutical from $67.00 to $74.00 and gave the company an “overweight” rating in a research report on Friday, August 21st. Guggenheim dropped their price target on shares of Ultragenyx Pharmaceutical from $43.00 to $35.00 and set a “buy” rating on the stock in a research report on Tuesday, August 4th. Evercore lowered shares of Ultragenyx Pharmaceutical from an “outperform” rating to an “in-line” rating and set a $16.00 price objective on the stock. in a research note on Thursday. Wall Street Zen upgraded shares of Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Finally, Robert W. Baird downgraded shares of Ultragenyx Pharmaceutical from an “outperform” rating to a “neutral” rating and lowered their target price for the stock from $40.00 to $16.00 in a research note on Thursday. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Ultragenyx Pharmaceutical has an average rating of “Moderate Buy” and an average target price of $36.63.

Ultragenyx Pharmaceutical Trading Up 3.0%

NASDAQ RARE opened at $15.30 on Thursday. The business’s 50-day moving average price is $27.76 and its two-hundred day moving average price is $24.97. Ultragenyx Pharmaceutical has a 12 month low of $13.81 and a 12 month high of $39.89. The firm has a market capitalization of $1.51 billion, a PE ratio of -2.62 and a beta of 0.31.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) earnings per share for the quarter, beating the consensus estimate of ($1.22) by $0.32. Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 81.79%.The company had revenue of $214.00 million during the quarter, compared to analysts’ expectations of $183.08 million. During the same quarter in the prior year, the firm posted ($1.17) earnings per share. The business’s quarterly revenue was up 28.5% on a year-over-year basis. As a group, analysts forecast that Ultragenyx Pharmaceutical will post -3.98 earnings per share for the current fiscal year.

Insider Activity at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, EVP Karah Parschauer sold 1,899 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $24.62, for a total value of $46,753.38. Following the completion of the sale, the executive vice president directly owned 94,462 shares in the company, valued at approximately $2,325,654.44. The trade was a 1.97% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Corsee Sanders sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $25.05, for a total value of $50,100.00. Following the completion of the transaction, the director directly owned 21,095 shares in the company, valued at approximately $528,429.75. This trade represents a 8.66% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 5.20% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Corient Private Wealth LP grew its holdings in Ultragenyx Pharmaceutical by 7.3% in the second quarter. Corient Private Wealth LP now owns 146,493 shares of the biopharmaceutical company’s stock worth $4,891,000 after purchasing an additional 9,949 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in Ultragenyx Pharmaceutical in the second quarter valued at $1,036,000. California State Teachers Retirement System raised its holdings in shares of Ultragenyx Pharmaceutical by 3,137.6% during the second quarter. California State Teachers Retirement System now owns 3,388,117 shares of the biopharmaceutical company’s stock valued at $113,129,000 after purchasing an additional 3,283,467 shares during the period. denkapparat Operations GmbH acquired a new position in shares of Ultragenyx Pharmaceutical during the second quarter valued at about $230,000. Finally, Nykredit A S acquired a new position in shares of Ultragenyx Pharmaceutical during the second quarter valued at about $154,000. 97.67% of the stock is owned by institutional investors.

Trending Headlines about Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Several analysts still see substantial potential upside after the selloff. Barclays maintained an “overweight” rating with a $32 price target, while Jefferies, Citigroup, TD Cowen, Canaccord Genuity, Cantor Fitzgerald and HC Wainwright retained bullish ratings despite sharply reducing their targets.
• Positive Sentiment: Ultragenyx is evaluating “significant” cost reductions following the trial failure, which could help preserve cash and improve the company’s financial outlook. Investors are also focusing on its existing commercial rare-disease portfolio. Ultragenyx to weigh significant cost cuts as Angelman drug fails key study
• Positive Sentiment: Unusually heavy call-option activity and speculation that Ultragenyx could become an acquisition target provide potential—but highly speculative—support for the stock. Ultragenyx potential M&A target
• Neutral Sentiment: Analyst views are increasingly divided. Goldman Sachs lowered its target to $19 and moved to “neutral,” while Barclays remains “overweight” at $32. Jefferies and Citi kept “buy” ratings but reduced targets to $28. The wide range reflects uncertainty over Ultragenyx’s post-trial growth prospects.
• Negative Sentiment: RBC downgraded the company to “hold,” while Bank of America, JPMorgan, Wells Fargo, Baird, Evercore, William Blair and others also reduced ratings or targets. Baird and Evercore now see only limited upside, signaling diminished confidence in the pipeline.
• Negative Sentiment: The Angelman syndrome failure creates greater dependence on Ultragenyx’s existing products and other pipeline programs. The company is weighing the future of the program, adding uncertainty around research spending, revenue growth and long-term valuation. Ultragenyx Angelman syndrome trial failure

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.